HC Wainwright Has Negative Forecast for PTGX FY2026 Earnings

Key Points

• HC Wainwright cut its FY2026 EPS forecast for Protagonist Therapeutics to $4.00 from $4.72, while projecting losses in Q4 2026, FY2027 and FY2028 before a return to profitability in later years.
• Protagonist’s latest quarter modestly beat expectations, reporting $2.29 EPS and $213.47 million in revenue, with revenue up 3,746.8% year over year.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $126.71, though insider selling and the lowered earnings outlook add caution.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Protagonist Therapeutics in a report released on Thursday, August 6th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $4.00 per share for the year, down from their previous estimate of $4.72. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $3.51 per share. HC Wainwright also issued estimates for Protagonist Therapeutics' Q4 2026 earnings at ($0.90) EPS, FY2027 earnings at ($2.80) EPS, FY2028 earnings at ($2.45) EPS, FY2029 earnings at $0.12 EPS and FY2030 earnings at $1.46 EPS.

Several other equities research analysts also recently commented on the company. Citigroup increased their price objective on Protagonist Therapeutics from $130.00 to $175.00 and gave the company a "buy" rating in a report on Thursday. The Goldman Sachs Group restated a "neutral" rating and set a $110.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Citizens Jmp upped their price target on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a "market outperform" rating in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Protagonist Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $126.71.

Protagonist Therapeutics Price Performance

NASDAQ:PTGX opened at $145.87 on Monday. Protagonist Therapeutics has a twelve month low of $50.49 and a twelve month high of $148.00. The firm has a market capitalization of $9.38 billion, a price-to-earnings ratio of 141.62 and a beta of 1.78. The stock's 50 day moving average price is $124.30 and its two-hundred day moving average price is $105.38.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.27 by $0.02. The firm had revenue of $213.47 million during the quarter, compared to analysts' expectations of $212.03 million. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The firm's revenue for the quarter was up 3746.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its position in shares of Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company's stock valued at $26,000 after buying an additional 156 shares in the last quarter. Greenline Wealth Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter worth approximately $27,000. Harbor Investment Advisory LLC bought a new position in Protagonist Therapeutics in the second quarter valued at approximately $89,000. EverSource Wealth Advisors LLC increased its stake in Protagonist Therapeutics by 63.0% in the first quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $96,000 after acquiring an additional 352 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its position in Protagonist Therapeutics by 222.4% during the fourth quarter. Hantz Financial Services Inc. now owns 951 shares of the company's stock valued at $83,000 after purchasing an additional 656 shares in the last quarter. Institutional investors own 98.63% of the company's stock.

Insider Activity

In related news, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the completion of the sale, the director directly owned 7,825 shares of the company's stock, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the business's stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total value of $7,509,000.00. Following the completion of the sale, the chief executive officer owned 523,478 shares of the company's stock, valued at $52,410,617.36. This trade represents a 12.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 102,000 shares of company stock worth $10,436,340 over the last three months. Insiders own 5.19% of the company's stock.

Key Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Protagonist reported quarterly earnings of $2.29 per share, exceeding the $2.27 analyst consensus, while revenue of $213.48 million also topped expectations. The results represent substantial year-over-year revenue growth and helped push PTGX to a new one-year high. Protagonist Therapeutics Reaches New 1-Year High on Earnings Beat
• Positive Sentiment: Citigroup raised its price target for PTGX to $175, signaling additional potential upside from recent trading levels and continued analyst confidence in the company’s outlook. Citigroup Raises Protagonist Therapeutics Price Target to $175
• Neutral Sentiment: Wall Street Zen changed its rating on Protagonist Therapeutics to Buy. Although the rating is bullish, the report describes the move as a downgrade, suggesting the change may reflect a less aggressive stance than the firm’s prior view. Protagonist Therapeutics Downgraded by Wall Street Zen to Buy
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to $4.00 from $4.72 and cut its fourth-quarter 2026 forecast to a loss of $0.90 per share from a loss of $0.76. The firm also projects losses in FY2027 and FY2028, adding pressure to near-term valuation despite its FY2026 estimate remaining above the broader consensus of $3.69. HC Wainwright Analysts Decrease Earnings Estimates for PTGX

About Protagonist Therapeutics

Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source